NAM supplementation was also capable of improving anti-PD-1-based immunotherapy in tumours otherwise refractory to anti-PD-1 treatment, effectively inhibiting tumour growth and significantly extending the survival time of the mice, again associated with significantly increased presence of TILs [250]. Here, PDCD1 is linked to neoplasm.